View Cart  

New Genzyme Gaucher’s Candidate Meets Phase III Endpoint

A A
Genzyme’s Phase III trial of eliglustat tartrate to treat Gaucher’s disease Type 1 has met its endpoint, setting the company up for a filing in the fourth quarter.

To View This Article:

Login

Subscribe To Drug Industry Daily